Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Biological Products: Reporting of Biological Product Deviations in Manufacturing; Forms FDA 3486 and 3486A, 4267-4269 [E7-1415]
Download as PDF
<![CDATA[
Federal Register / Vol. 72, No. 19 / Tuesday, January 30, 2007 / Notices
Dated: January 22, 2007.
Judith Sparrow,
Director, American Health Information
Community, Office of Programs and
Coordination, Office of the National
Coordinator for Health Information
Technology.
[FR Doc. 07–393 Filed 1–29–07; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the National Coordinator for
Health Information Technology;
American Health Information
Community Population CARE and
Clinical Care Connections Workgroup
Meeting
BILLING CODE 4150–24–M
ACTION:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the National Coordinator for
Health Information Technology;
American Health Information
Community Chronic Care Workgroup
Meeting
ACTION:
Announcement of meeting.
SUMMARY: This notice announces the
13th meeting of the American Health
Information Community Chronic Care
Workgroup in accordance with the
Federal Advisory Committee Act (Pub.
L. No. 92–463, 5 U.S.C.; App.)
February 15, 2007, from 1 p.m.
to 4 p.m.
DATES:
Mary C. Switzer Building
(330 C Street, SW., Washington, DC
20201), Conference Room 4090 (please
bring photo ID for entry to a Federal
building).
ADDRESSES:
FOR FURTHER INFORMATION:
https://www.hhs.gov/healthit/ahic/
chroniccare/.
The
Workgroup will continue to discuss
possible Recommendations to the
American Health Information
Community, and medical/legal issues
and challenges facing the use of remote
monitoring and secure messaging
technologies.
The meeting will be available via
Internet access. For additional
information, go to https://www.hhs.gov/
healthit/ahic/chroniccare/
cc_instruct.html.
ycherry on PROD1PC64 with NOTICES
SUPPLEMENTARY INFORMATION:
Dated: January 24, 2007.
Judith Sparrow,
Director, American Health Information
Community, Office of Programs and
Coordination, Office of the National
Coordinator for Health Information
Technology.
[FR Doc. 07–394 Filed 1–29–07; 8:45 am]
BILLING CODE 4150–24–M
Announcement of meeting.
SUMMARY: This notice announces the
13th meeting of the American Health
Information Community Population
Care and Clinical Care Connections
Workgroup [formerly Biosurveillance
Workgroup] in accordance with the
Federal Advisory Committee Act (Pub.
L. No. 92–463, 5 U.S.C., App.)
DATES: February 2, 2007, from 10 a.m.
to 3 p.m.
ADDRESSES: Mary C. Switzer Building
(330 C Street, SW., Washington, DC
20201), Conference Room 4090 (please
bring photo ID for entry to a Federal
building)
FOR FURTHER INFORMATION CONTACT:
http:/www.hhs.gov/healthit/ahic/
biosurveillance/.
SUPPLEMENTARY INFORMATION: The
Workgroup will discuss the priority
areas of Adverse Events and Response
Management.
The meeting will be available via
Internet access. For additional
information, go to https://www.hhs.gov/
healthit/ahic/biosurveillance/
bio_instruct.html.
Dated: January 22, 2007.
Judith Sparrow,
Director, American Health Information
Community, Office of Programs and
Coordination, Office of the National
Coordinator for Health Information
Technology.
[FR Doc. 07–395 Filed 1–29–07; 8:45 am]
BILLING CODE 4150–24–M
15:36 Jan 29, 2007
Jkt 211001
8:30 a.m.–5 p.m., February 15, 2007.
8:30 a.m.–4 p.m., February 16, 2007.
Place: Centers for Disease Control and
Prevention (CDC) Roybal Campus, Bldg 19,
Auditorium B3, 1600 Clifton Road, Atlanta,
GA 30333.
Status: Open to the public, limited only by
the space available.
Purpose: The Committee is charged with
providing advice and guidance to the
Secretary, the Assistant Secretary for Health,
the Director, CDC, and the Director, National
Center for Infectious Diseases (NCID),
regarding (1) the practice of hospital
infection control; (2) strategies for
surveillance, prevention, and control of
infections (e.g., nosocomial infections),
antimicrobial resistance, and related events
in settings where healthcare is provided; and
(3) periodic updating of guidelines and other
policy statements regarding prevention of
healthcare-associated infections and
healthcare-related conditions.
Matters to Be Discussed: Agenda items will
include: Information Technology Standards
Update; National Quality Forum Update and
Prevention Epidemiology Centers Update.
Agenda items are subject to change as
priorities dictate.
Contact Person for More Information:
Harriette Lynch, Committee Management
Specialist, HICPAC, Division of Healthcare
Quality Promotion, NCID, CDC, 1600 Clifton
Road, NE, M/S A–07, Atlanta, Georgia 30333,
telephone 404–639–4035.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Dated: January 23, 2007.
Elaine L. Baker,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. E7–1393 Filed 1–29–07; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Food and Drug Administration
[Docket No. 2006N–0421]
Healthcare Infection Control Practices
Advisory Committee (HICPAC):
Meeting
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following meeting of the
aforementioned committee.
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Biological
Products: Reporting of Biological
Product Deviations in Manufacturing;
Forms FDA 3486 and 3486A
AGENCY:
Name: Healthcare Infection Control
Practices Advisory Committee (HICPAC).
Times and Dates:
VerDate Aug<31>2005
4267
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
E:\FR\FM\30JAN1.SGM
30JAN1
4268
Federal Register / Vol. 72, No. 19 / Tuesday, January 30, 2007 / Notices
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by March 1,
2007.
To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–6974.
FOR FURTHER INFORMATION CONTACT:
Jonna Capezzuto, Office of the Chief
Information Officer (HFA–250), Food
and Drug Administration, 5600 Fishers
Lane, Rockville, MD 20857,301–827–
4659.
ADDRESSES:
In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
SUPPLEMENTARY INFORMATION:
Biological Products: Reporting of
Biological Product Deviations in
Manufacturing; Forms FDA 3486 and
3486A (OMB Control Number 0910–
0458)—Extension
ycherry on PROD1PC64 with NOTICES
Under section 351 of the Public
Health Service Act (42 U.S.C. 262), all
biological products, including human
blood and blood components, offered
for sale in interstate commerce must be
licensed and meet standards designed to
ensure the continued safety, purity, and
potency of such products. In addition,
the Federal Food, Drug, and Cosmetic
Act (the act) (21 U.S.C. 351) provides
that drugs and devices (including
human blood and blood components)
are adulterated if they do not conform
with Current Good Manufacturing
Practice (CGMP) assuring that they meet
the requirements of the act. All
establishments manufacturing biological
products including human blood and
blood components must comply with
the applicable CGMP regulations (parts
211, 606, and 820 (21 CFR parts 211,
606, and 820)). Transfusion services are
required under 42 CFR 493.1271 to
comply with 21 CFR parts 606 and 640
as they pertain to the performance of
manufacturing activities. FDA regards
biological product deviation (BPD)
reporting to be an essential tool in its
directive to protect public health by
establishing and maintaining
VerDate Aug<31>2005
15:36 Jan 29, 2007
Jkt 211001
surveillance programs that provide
timely and useful information.
Section 600.14 requires the
manufacturer who holds the biological
product license, for other than human
blood and blood components, and who
had control over the product when the
deviation occurred, to report to the
Center for Biologics Evaluation and
Research (CBER) or to the Center for
Drugs Evaluation and Research (CDER)
as soon as possible but not to exceed 45
calendar days after acquiring
information reasonably suggesting that a
reportable event has occurred. Section
606.171 requires a licensed
manufacturer of human blood and blood
components, including Source Plasma;
an unlicensed registered blood
establishment; or a transfusion service
who had control over the product when
the deviation occurred, to report to
CBER as soon as possible but not to
exceed 45 calendar days after acquiring
information reasonably suggesting that a
reportable event has occurred. The BPD
reporting under 21 CFR 1271.350(b) for
human cells, tissues, and cellular and
tissue-based products is approved under
OMB control number 0910–0559
(expires November 30, 2007). Form FDA
3486 is used to submit BPDs under
these regulations.
Respondents to this collection of
information are the licensed
manufacturers of biological products
other than human blood and blood
components, licensed manufacturers of
blood and blood components including
Source Plasma, unlicensed registered
blood establishments, and transfusion
services. Based on information from
FDA’s database, there are an estimated
147 licensed manufacturers of biological
products other than human blood and
blood components, 194 licensed
manufacturers of human blood and
blood components, including Source
Plasma, and 1,230 unlicensed registered
blood establishments. Based on the
Center for Medicare and Medicaid
Services records, there are an estimated
4,980 transfusion services. The number
of licensed manufacturers and total
annual responses under § 600.14
include the estimates for both CBER and
CDER. The number of total annual
responses is based on the number of
BPD reports FDA received in fiscal year
2005. The rate of submission is not
expected to change significantly in the
next few years. Based on information
from industry, the estimated average
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
time to complete a deviation report is 2
hours. The availability of the
standardized report form, Form FDA
3486, and the ability to submit this
report electronically to CBER (CDER
does not currently accept electronic
filings) further streamlines the report
submission process.
CBER is developing an addendum to
Form FDA 3486. The web-based
addendum (Form FDA 3486A) would
request additional information when a
BPD report has been reviewed by FDA
and evaluated as a possible recall. The
additional information requested would
include information not contained in
the Form FDA 3486 such as: (1)
Distribution pattern, (2) method of
consignee notification, (3) consignee(s)
of products for further manufacture, (4)
additional product information, and (5)
updated product disposition. This
information would be requested by
CBER through e-mail notification to the
submitter of the BPD report. This
information would be used by CBER for
purposes of recall classification. We
plan to use Form FDA 3486A for only
biological products regulated by CBER.
We do not plan to use this form for
biological products regulated by CDER
because they receive very few BPD
reports and do not accept electronic
filings. CBER estimates that 5 percent of
the total BPD reports submitted to CBER
would need additional information
submitted in the addendum. CBER
estimates it would take between 15 to 45
minutes to complete the addendum. For
calculation purposes, CBER is using
one-half hour.
Activities such as investigating,
changing standard operating procedures
or processes, and followup are currently
required under part 211 (approved
under OMB control no. 0910–0139,
expires September 30, 2008); part 606
(approved under OMB control no. 0910–
0116, expires December 31, 2008); and
part 820 (approved under OMB control
no. 0910–0073, expires September 30,
2007) and, therefore, are not included in
the burden calculation for the separate
requirement of submitting a BPD report
to FDA.
In the Federal Register of October 31,
2006, (71 FR 63772), FDA published a
60-day notice requesting public
comment on the information collection
provisions. No comments were received.
FDA estimates the burden of this
collection of information as follows:
E:\FR\FM\30JAN1.SGM
30JAN1
4269
Federal Register / Vol. 72, No. 19 / Tuesday, January 30, 2007 / Notices
TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN 1
21 CFR Section
FDA Form
Number
No. of
Respondents
Annual Frequency
per Response
Total Annual
Responses
Hours per
Responses
Total Hours
600.14
3486
147
2.73
401
2.0
802
606.171 2
3486
194
169.89
32,958
2.0
65,916
606.171 3
3486
6,210
1.50
9,311
2.0
18,622
3486A 4
6,551
0.33
2,133
0.5
1,067
Total
86,407
1 There
are no capital costs or maintenance costs associated with this collection of information.
manufacturers of human blood and blood components, including Source Plasma.
registered blood establishments and transfusion services (1,230 + 4,980 = 6,210).
4 Five percent of the total annual responses to CBER (42,653 x 0.05 = 2,133).
2 Licensed
3 Unlicensed
Dated: January 24, 2007.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E7–1415 Filed 1–29–07; 8:45 am]
Lane, Rockville, MD 20857, 301–594–
2041.
SUPPLEMENTARY INFORMATION:
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2005N–0105]
James T. Kimball; Denial of Hearing;
Final Debarment Order
AGENCY:
Food and Drug Administration,
HHS.
ycherry on PROD1PC64 with NOTICES
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is denying Mr.
James T. Kimball’s request for a hearing
and is issuing a final order under the
Federal Food, Drug, and Cosmetic Act
(the act) permanently debarring Mr.
James T. Kimball from providing
services in any capacity to a person that
has an approved or pending drug
product application. FDA bases this
order on a finding that Mr. Kimball was
convicted of felonies under Federal law
for conduct relating to the regulation of
a drug product under the act. In
addition, Mr. Kimball has failed to file
with the agency information and
analyses sufficient to create a basis for
a hearing concerning this action.
DATES: This order is effective January
30, 2007.
ADDRESSES: Submit applications for
termination of debarment to the
Division of Dockets Management (HFA–
305), Food and Drug Administration,
5630 Fishers Lane, rm. 1061, Rockville,
MD 20852.
FOR FURTHER INFORMATION CONTACT:
Mary Catchings, Center for Drug
Evaluation and Research (HFD–7), Food
and Drug Administration, 5600 Fishers
VerDate Aug<31>2005
15:36 Jan 29, 2007
Jkt 211001
I. Background
On May 24, 2000, a jury found Mr.
Kimball guilty of one count of
conspiring to commit offenses against
the United States and the Florida
Department of Health, a Federal felony
offense under 18 U.S.C. 371; six counts
of distributing a misbranded drug into
interstate commerce, a Federal felony
offense under 21 U.S.C. 331(a); and one
count of making a false statement in a
matter within the jurisdiction of a
Federal agency, a Federal felony offense
under 18 U.S.C. 1001. On October 19,
2000, the U.S. District Court for the
Middle District of Florida entered
judgment and sentenced Mr. Kimball for
these offenses.
The bases for these convictions were
Mr. Kimball’s knowing and willful
participation, including conspiring, to
violate Federal laws in connection with
the distribution of a misbranded drug,
deprenyl, into interstate commerce, and
false statements he made to the U.S.
Customs Service about shipments of
deprenyl for export. The drug deprenyl
was misbranded because it contained
selegiline, the active ingredient of a
prescription drug Eldepryl, but was
dispensed without a prescription issued
by a licensed practitioner.
As a result of these convictions, FDA
served Mr. Kimball by certified letter on
April 25, 2005,1 a proposal to
permanently debar him from providing
services in any capacity to a person that
has an approved or pending drug
1 The certified letter was mailed to the prison
facility where records indicated that Mr. Kimball
was incarcerated, and the return receipt was signed
on April 25, 2005, by an employee at the facility.
In his request for hearing, Mr. Kimball stated that
he received the letter on May 5, 2005. The delivery
dates do not alter the nature of Mr. Kimball’s
request for a hearing or our application of summary
judgement in this matter.
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
product application. The notice also
offered Mr. Kimball an opportunity to
request a hearing on the debarment
proposal. The debarment proposal was
based on a finding, under section
306(a)(2)(B) of the act (21 U.S.C.
335a(a)(2)(B)), that Mr. Kimball was
convicted of felonies under Federal law
for conduct relating to the regulation of
a drug product under the act.
The certified letter also informed Mr.
Kimball that his request for a hearing
could not rest upon mere allegations or
denials, but must present specific facts
showing that there was a genuine and
substantial issue of fact requiring a
hearing. The letter also informed Mr.
Kimball that the only material issue of
fact was whether he was convicted as
alleged in the letter, and that the facts
underlying his conviction are not at
issue in this proceeding. Finally, the
letter informed Mr. Kimball that if it
conclusively appeared from the face of
the information and factual analyses in
his request for a hearing that there was
no genuine and substantial issue of fact
that precluded the order of debarment,
FDA would enter summary judgment
against him and deny his request for a
hearing.
In a letter dated May 16, 2005, Mr.
Kimball responded to the certified letter
by requesting a hearing.
II. Denial of Hearing
In his May 16, 2005, request for a
hearing, Mr. Kimball does not present
any arguments or information to show
why he should not be debarred. Mr.
Kimball merely states that: (1) He ‘‘was
not convicted pursuant to the
statements set forth in FDA’s alleged
notice’’, (2) the allegations of his
convictions are incorrect, and (3) his
conviction does not mandate his
debarment. Such statements do not
create a basis for a hearing because
hearings will not be granted on mere
allegations, denials, or general
E:\FR\FM\30JAN1.SGM
30JAN1
]]>Agencies
[Federal Register Volume 72, Number 19 (Tuesday, January 30, 2007)]
[Notices]
[Pages 4267-4269]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-1415]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 2006N-0421]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Biological Products:
Reporting of Biological Product Deviations in Manufacturing; Forms FDA
3486 and 3486A
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of
[[Page 4268]]
information has been submitted to the Office of Management and Budget
(OMB) for review and clearance under the Paperwork Reduction Act of
1995.
DATES: Fax written comments on the collection of information by March
1, 2007.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
FAX: 202-395-6974.
FOR FURTHER INFORMATION CONTACT: Jonna Capezzuto, Office of the Chief
Information Officer (HFA-250), Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857,301-827-4659.
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
Biological Products: Reporting of Biological Product Deviations in
Manufacturing; Forms FDA 3486 and 3486A (OMB Control Number 0910-
0458)--Extension
Under section 351 of the Public Health Service Act (42 U.S.C. 262),
all biological products, including human blood and blood components,
offered for sale in interstate commerce must be licensed and meet
standards designed to ensure the continued safety, purity, and potency
of such products. In addition, the Federal Food, Drug, and Cosmetic Act
(the act) (21 U.S.C. 351) provides that drugs and devices (including
human blood and blood components) are adulterated if they do not
conform with Current Good Manufacturing Practice (CGMP) assuring that
they meet the requirements of the act. All establishments manufacturing
biological products including human blood and blood components must
comply with the applicable CGMP regulations (parts 211, 606, and 820
(21 CFR parts 211, 606, and 820)). Transfusion services are required
under 42 CFR 493.1271 to comply with 21 CFR parts 606 and 640 as they
pertain to the performance of manufacturing activities. FDA regards
biological product deviation (BPD) reporting to be an essential tool in
its directive to protect public health by establishing and maintaining
surveillance programs that provide timely and useful information.
Section 600.14 requires the manufacturer who holds the biological
product license, for other than human blood and blood components, and
who had control over the product when the deviation occurred, to report
to the Center for Biologics Evaluation and Research (CBER) or to the
Center for Drugs Evaluation and Research (CDER) as soon as possible but
not to exceed 45 calendar days after acquiring information reasonably
suggesting that a reportable event has occurred. Section 606.171
requires a licensed manufacturer of human blood and blood components,
including Source Plasma; an unlicensed registered blood establishment;
or a transfusion service who had control over the product when the
deviation occurred, to report to CBER as soon as possible but not to
exceed 45 calendar days after acquiring information reasonably
suggesting that a reportable event has occurred. The BPD reporting
under 21 CFR 1271.350(b) for human cells, tissues, and cellular and
tissue-based products is approved under OMB control number 0910-0559
(expires November 30, 2007). Form FDA 3486 is used to submit BPDs under
these regulations.
Respondents to this collection of information are the licensed
manufacturers of biological products other than human blood and blood
components, licensed manufacturers of blood and blood components
including Source Plasma, unlicensed registered blood establishments,
and transfusion services. Based on information from FDA's database,
there are an estimated 147 licensed manufacturers of biological
products other than human blood and blood components, 194 licensed
manufacturers of human blood and blood components, including Source
Plasma, and 1,230 unlicensed registered blood establishments. Based on
the Center for Medicare and Medicaid Services records, there are an
estimated 4,980 transfusion services. The number of licensed
manufacturers and total annual responses under Sec. 600.14 include the
estimates for both CBER and CDER. The number of total annual responses
is based on the number of BPD reports FDA received in fiscal year 2005.
The rate of submission is not expected to change significantly in the
next few years. Based on information from industry, the estimated
average time to complete a deviation report is 2 hours. The
availability of the standardized report form, Form FDA 3486, and the
ability to submit this report electronically to CBER (CDER does not
currently accept electronic filings) further streamlines the report
submission process.
CBER is developing an addendum to Form FDA 3486. The web-based
addendum (Form FDA 3486A) would request additional information when a
BPD report has been reviewed by FDA and evaluated as a possible recall.
The additional information requested would include information not
contained in the Form FDA 3486 such as: (1) Distribution pattern, (2)
method of consignee notification, (3) consignee(s) of products for
further manufacture, (4) additional product information, and (5)
updated product disposition. This information would be requested by
CBER through e-mail notification to the submitter of the BPD report.
This information would be used by CBER for purposes of recall
classification. We plan to use Form FDA 3486A for only biological
products regulated by CBER. We do not plan to use this form for
biological products regulated by CDER because they receive very few BPD
reports and do not accept electronic filings. CBER estimates that 5
percent of the total BPD reports submitted to CBER would need
additional information submitted in the addendum. CBER estimates it
would take between 15 to 45 minutes to complete the addendum. For
calculation purposes, CBER is using one-half hour.
Activities such as investigating, changing standard operating
procedures or processes, and followup are currently required under part
211 (approved under OMB control no. 0910-0139, expires September 30,
2008); part 606 (approved under OMB control no. 0910-0116, expires
December 31, 2008); and part 820 (approved under OMB control no. 0910-
0073, expires September 30, 2007) and, therefore, are not included in
the burden calculation for the separate requirement of submitting a BPD
report to FDA.
In the Federal Register of October 31, 2006, (71 FR 63772), FDA
published a 60-day notice requesting public comment on the information
collection provisions. No comments were received.
FDA estimates the burden of this collection of information as
follows:
[[Page 4269]]
Table 1.--Estimated Annual Reporting Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
FDA Form No. of Annual Frequency Total Annual Hours per
21 CFR Section Number Respondents per Response Responses Responses Total Hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
600.14 3486 147 2.73 401 2.0 802
--------------------------------------------------------------------------------------------------------------------------------------------------------
606.171 \2\ 3486 194 169.89 32,958 2.0 65,916
--------------------------------------------------------------------------------------------------------------------------------------------------------
606.171 \3\ 3486 6,210 1.50 9,311 2.0 18,622
--------------------------------------------------------------------------------------------------------------------------------------------------------
3486A \4\ 6,551 0.33 2,133 0.5 1,067
--------------------------------------------------------------------------------------------------------------------------------------------------------
Total .............. ................. ................. ................. ................. 86,407
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or maintenance costs associated with this collection of information.
\2\ Licensed manufacturers of human blood and blood components, including Source Plasma.
\3\ Unlicensed registered blood establishments and transfusion services (1,230 + 4,980 = 6,210).
\4\ Five percent of the total annual responses to CBER (42,653 x 0.05 = 2,133).
Dated: January 24, 2007.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E7-1415 Filed 1-29-07; 8:45 am]
BILLING CODE 4160-01-S
